Mr. Anders Essen-Möller is a Swedish serial inventor and entrepreneur, focusing on the development of treatments for autoimmune disease, in particular Diabetes. He earned a master’s degree in Electronics at the Technical University of Lund, Sweden and proceeded with medical studies at the Karolinska Institutet in Stockholm. After holding various management positions within the MedTech space, Anders Essen-Möller founded the public MedTech company Synectics Medical. When his daughter My was diagnosed with Type-1 Diabetes, Synectics Medical was sold to Medtronic Inc., whereas the proceeds were used to found Diamyd Medical, a public company dedicated to the development of diabetes therapies. License agreements for using GAD65 as an antigen specific tolerization therapy were signed with UCLA, University of Florida and University of Washington.
Diamyd Medical has had several strategic holdings and successful investment exits (Protein Sciences, Companion Medical), with current interests in the AI technology development company MainlyAI and the public stem cell company Next Cell Pharma.
Diamyd Medical is now conducting a pivotal precision medicine Phase III clinical trial, Diagnode-3, evaluating the antigen-specific immunotherapy Diamyd® for the treatment of autoimmune diabetes, in individuals carrying a common risk gene (haplotype DR3-DQ2).
Dr. Åsa Wallin, has 10+ years experience of business development and innovation management of academic research, and is currently Vinnova Wallenberg Senior Fellow at Nordic Innovation House, Silicon Valley. She holds a PhD from Linköping University. Her role at Linköping University is to explore, and strategically develop collaborations and presence in the US.